deltatrials
Completed PHASE3 NCT00003293

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse

Sponsor: Pfizer

Conditions Brain and Central Nervous System Tumors
Interventions leflunomide procarbazine hydrochloride
Updated 6 times since 2017 Last updated: Sep 10, 2012 Started: Feb 28, 1998 Primary completion: May 31, 2001 Completion: May 31, 2001

Listed as NCT00003293, this PHASE3 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by Pfizer, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Ann Arbor, United States, Augusta, United States, Boston, United States, Chapel Hill, United States, Chicago, United States, Cincinnati, United States, Columbus, United States, Dallas, United States, Denver, United States and 22 more location s